Cold-fX
Brand logo | |
| Inventor | Afexa Life Sciences Inc. |
|---|---|
| Inception | 1999 |
| Manufacturer | Bausch Health (formerly Valeant Pharmaceuticals International) |
| Available | Available |
| Current supplier | Bausch & Lomb |
| Website | www |
Cold-Fx is a product derived from the roots of North American ginseng (Panax quinquefolius). It was formulated by Jacqueline Shan, and originally manufactured by her company, Afexa Life Sciences (formerly called CV Technologies). Afexa was acquired by Valeant Pharmaceuticals in 2011. Bausch & Lomb, acquired by Valeant, is the marketing company for Cold-Fx, as of 2025.
There is little evidence to support that Cold-Fx is effective in the common cold. All trials have been done by the manufacturer and there has been poor data reporting. According to Health Canada's Natural Health Product Directorate records, the company claims that it may "help reduce the frequency, severity and duration of cold and flu symptoms by boosting the immune system". Cold-Fx is licensed by Health Canada as a natural health product.